COHERUS ONCOLOGY INC (CHRS) competitors & alternatives
Health Care · NASDAQ
COHERUS ONCOLOGY INC (CHRS)'s top competitors and alternatives — its most similar public companies — include Bristol Myers Squibb (BMY), ASTRAZENECA PLC (AZN), BICARA THERAPEUTICS INC (BCAX), ARCUS BIOSCIENCES INC (RCUS), Exelixis (EXEL), CRESCENT BIOPHARMA INC (CBIO), ALX ONCOLOGY HOLDINGS INC (ALXO), AGENUS INC (AGEN), DELCATH SYS INC (DCTH), Pyxis Oncology, Inc. (PYXS), COMPASS THERAPEUTICS (CMPX) and REPLIMUNE GROUP INC (REPL). These are COHERUS ONCOLOGY INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top CHRS competitors & alternatives
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
BICARA THERAPEUTICS INCBCAXHealth Care
Bicara Therapeutics is developing a pipeline of bifunctional antibodies that precisely target and neutralize both EGFR and TGF-β pathways to improve treatment…
$27.96 (as of 2026-07-22) · market cap $1.9B
-
ARCUS BIOSCIENCES INCRCUSHealth Care
A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in…
$29.97 (as of 2026-07-22) · market cap $3.7B
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
CRESCENT BIOPHARMA INCCBIOHealth Care
Crescent Biopharma is a clinical-stage oncology company developing a novel PD-1 x VEGF bispecific antibody and a portfolio of antibody-drug conjugates to…
$15.83 (as of 2026-07-22) · market cap $615M
-
ALX ONCOLOGY HOLDINGS INCALXOHealth Care
An early-stage immuno-oncology biotech advancing a next-generation CD47 blocker designed to restore macrophage tumor-killing when combined with targeted cancer…
$2.02 (as of 2026-07-22) · market cap $272M
-
AGENUS INCAGENHealth Care
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term…
$5.53 (as of 2026-07-22) · market cap $232M
-
DELCATH SYS INCDCTHHealth Care
Interventional oncology company bringing a catheter-based chemotherapy delivery system to market for treating liver cancers, anchored by the newly FDA-approved…
$12.53 (as of 2026-07-22) · market cap $433M
-
Pyxis Oncology, Inc.PYXSHealth Care
Pyxis Oncology is a clinical-stage biopharma developing innovative antibody-drug conjugates (ADCs) that target the tumor microenvironment to improve efficacy…
$2.53 (as of 2026-07-22) · market cap $160M
-
COMPASS THERAPEUTICSCMPXHealth Care
Compass Therapeutics is a clinical-stage oncology company developing a pipeline of bispecific and agonistic antibodies designed to treat solid tumors by…
$2.04 (as of 2026-07-22) · market cap $367M
-
REPLIMUNE GROUP INCREPLHealth Care
Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in…
$10.75 (as of 2026-07-22) · market cap $918M
Not quite? Describe exactly what you want →
Peers are COHERUS ONCOLOGY INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: COHERUS ONCOLOGY INC (CHRS).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.